%PDF-1.4
%
99 0 obj
<>
endobj
96 0 obj
<>
endobj
172 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-03-02T11:44:23Z
2024-03-29T03:33:46-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T03:33:46-07:00
application/pdf
Heather
2003-303.march
uuid:e4c66bca-1dd1-11b2-0a00-ad09276d7200
uuid:e4c66bcc-1dd1-11b2-0a00-b80000000000
endstream
endobj
85 0 obj
<>
endobj
86 0 obj
<>
endobj
100 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 65 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 67 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 69 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 71 0 R/Type/Page>>
endobj
25 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 73 0 R/Type/Page>>
endobj
38 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 75 0 R/Type/Page>>
endobj
51 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 77 0 R/Type/Page>>
endobj
54 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 79 0 R/Type/Page>>
endobj
202 0 obj
[206 0 R]
endobj
203 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.8 g
/T1_0 18 Tf
0.6114 0.7912 -0.7912 0.6114 35.383 35.2215 Tm
(Personal, non-commercial use only. The Journal of Rheumatology. Copyrigh\
t \251 2004. All rights reserved.)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 61 714.5293 Tm
[(8.)-875.1 (W)39.8 (ilcox CM, Shalek KA, Cotsonis G. Striking prevalence of )]TJ
1.675 -1.25 Td
[(over)19.7 (-the-counter nonsteroidal anti-inflammatory drug use in)]TJ
0 -1.25 TD
[(patients with upper gastrointestinal hemorrhage. )54.8 (Arch Intern Med)]TJ
0 Tc 0 Tw T*
(1994;15:42-5.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875.1 (Clive DM, Stof)17.7 (f JS. Renal syndromes associated with nonsteroidal)]TJ
1.675 -1.25 Td
(anti-inflammatory drugs. N Engl J Med 1984;310:563-72.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (Brandt K. Nonsteroidal anti-inflammatory drugs and articular )]TJ
2.175 -1.25 Td
(cartilage. J Rheumatol 1987;14 Suppl:132-3.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Petrella RJ, DiSilvestro MD, Hildebrand C. Ef)17.7 (fects of hyaluronate)]TJ
2.1381 -1.25 Td
(sodium on pain and physical functioning in osteoarthritis of the)Tj
T*
(knee: a randomized, double-blind, placebo-controlled clinical trial.)Tj
T*
(Arch Intern Med 2002;162:292-8.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Kovacs I, Bender )17.7 (T)74 (.)-0.1 ( )17.7 (The therapeutic ef)17.7 (fects of Cserkeszolo thermal)]TJ
2.175 -1.25 Td
(water in osteoarthritis of the knee: a double blind, controlled,)Tj
T*
[(follow-up study)64.8 (. Rheumatol Int 2002;21:218-21.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Kremer JM, Bigauoette J, Michalek )54.8 (A)128.9 (V)128.9 (, et al. Ef)17.7 (fects of )]TJ
2.175 -1.25 Td
(manipulation of dietary fatty acids on clinical manifestations of)Tj
T*
(rheumatoid arthritis. Lancet 1985;1:184-7.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Kremer JM, Jubiz )17.7 (W)91.8 (, Michalek )54.8 (A, et al. Fish-oil fatty acid )]TJ
2.175 -1.25 Td
[(supplementation in active rheumatoid arthritis. )54.8 (A)-220.1 (double-blinded,)]TJ
T*
[(controlled, crossover study)64.9 (. )54.8 (Ann Intern Med 1987;106:497-503.)]TJ
-2.175 -1.25 Td
[(15.)-875.1 (Kremer JM. N-3 fatty acid supplements in rheumatoid arthritis. )54.8 (Am)]TJ
2.175 -1.25 Td
(J Clin Nutr 2000;71 Suppl:349S-51S.)Tj
-2.175 -1.25 Td
[(16.)-875.1 (Diehl HW)91.7 (, May EL. Cetyl myristoleate isolated from swiss albino)]TJ
2.175 -1.25 Td
(mice: an apparent protective agent against adjuvant arthritis in rats.)Tj
T*
(J Pharm Sci 1994;83:296-9.)Tj
-2.175 -1.25 Td
[(17.)-875.1 (Hesslink R, )54.8 (Armstrong D, Nagendran MV)128.8 (, Sreevatsan S, Barathur)]TJ
2.175 -1.25 Td
(R. Cetylated fatty acids improve knee function in patients with)Tj
T*
(osteoarthritis. J Rheumatol 2002;29:1708-12.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (Hochber)17.7 (g MC, )54.8 (Altman RD, Brandt KD, et al. Guidelines for the)]TJ
2.175 -1.25 Td
(medical treatment of osteoarthritis. II: osteoarthritis of the knee.)Tj
T*
(Arthritis Rheum 1995;38:1541-6.)Tj
-2.175 -1.25 Td
[(19.)-875.1 (Podsiadlo D, Richardson S. )17.7 (The timed \322up & go\323: a test of basic)]TJ
2.175 -1.25 Td
[(functional mobility for frail elderly persons. J )54.8 (Am Geriatr Soc)]TJ
0 Tc 0 Tw T*
(1991;39:142-8.)Tj
-0.00011 Tc 0.02499 Tw 30.825 42.5 Td
[(20.)-875.1 (Curtis CL, Hughes CE, Flannery CR, et al. N-3 fatty acids )]TJ
2.175 -1.25 Td
(specifically modulate catabolic factors involved with articular )Tj
T*
(cartilage degradation. J Biol Chem 2000;275:721-4.)Tj
-2.175 -1.25 Td
[(21.)-875.1 (Kremer JM. Ef)17.7 (fects of modulation of inflammatory and immune)]TJ
2.175 -1.25 Td
(parameters in patients with rheumatic and inflammatory disease)Tj
T*
(receiving dietary supplementation of N-3 and N-6 fatty acids.)Tj
T*
(Lipids 1996;31 Suppl:S243-7.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (Heraud F)79.7 (, Heraud )54.8 (A, Harmand MF)79.7 (. )54.8 (Apoptosis in normal and)]TJ
2.175 -1.25 Td
[(osteoarthritic human articular cartilage. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(2000;59:959-65.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(23.)-875.1 (Kaufman KR, Hughes C, Morrey BF)79.7 (, Morrey M, )54.8 (An K. Gait )]TJ
2.175 -1.25 Td
(characteristics of patients with knee osteoarthritis. J Biomech)Tj
0 Tc 0 Tw T*
(2001;34:907-15.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(24.)-875.1 (Hassan BS, Doherty SA, Mockett S, Doherty M. Ef)17.7 (fect of pain)]TJ
2.175 -1.25 Td
[(reduction on postural sway)64.8 (, proprioception, and quadriceps strength)]TJ
T*
[(in subjects with knee osteoarthritis. )54.8 (Ann Rheum Dis 2002;61:422-8.)]TJ
-2.175 -1.25 Td
[(25.)-875.1 (Jadelis K, Miller ME, Ettinger )17.7 (WH, Messier SP)110.7 (. Strength, balance,)]TJ
2.175 -1.25 Td
[(and the modifying ef)17.7 (fects of obesity and knee pain: results from the)]TJ
T*
[(Observational )54.7 (Arthritis Study in Seniors \(OASIS\). J )54.7 (Am Geriatr)]TJ
0 Tc T*
(Soc 2001;49:884-91.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(26.)-875.1 (Messier SP)110.7 (, Glasser JL, Ettinger )17.7 (WH, Craven )17.7 (TE, Miller ME.)]TJ
2.175 -1.25 Td
(Declines in strength and balance in older adults with chronic knee)Tj
T*
[(pain: a 30-month longitudinal, observational study)64.8 (. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2002;47:141-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(27.)-875.1 (T)69.9 (opp R, )17.7 (W)79.9 (oolley S, Khuder S, et al. Predictors of four functional)]TJ
2.175 -1.25 Td
(tasks in patients with osteoarthritis of the knee. Orthop Nurs)Tj
0 Tc 0 Tw T*
(2000;19:49-58.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(28.)-875.1 (McGibbon CA, Krebs DE. Compensatory gait mechanics in)]TJ
2.175 -1.25 Td
(patients with unilateral knee arthritis. J Rheumatol 2002;29:2410-9.)Tj
-2.175 -1.25 Td
[(29.)-875.1 (Goats GC, Keir KA. Connective tissue massage. Br J Sports Med)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(1991;25:131-3.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2004; 31:4)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(774)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.09 396.47 -10.83 re
f*
0.5 w
109.25 59.09 396.47 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
79 0 obj
<>stream
8;Z\7$#[X7%+G5@W:(-f9p)`Hj_09`J;>(da'G#h78ZC&Lg?&>^&naV@+pF0(J&BcGF;pY
/>Qhe3Ci@,[HgfbM#LQB;biKbJ9gB=q".`P3W/5cN9jN;:F\Ot
BXZE@A^e47X.oAUsZn>YV+)e%LmN7<4XI5Y$aJKWqF[S3C5*1?[9A]cckJgLk\8o>YQ,
1t_9nqHJYg1`D?CUX
endstream
endobj
83 0 obj
[/Indexed/DeviceRGB 255 82 0 R]
endobj
82 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
138 0 obj
<>
endobj
107 0 obj
<>
endobj
102 0 obj
<>
endobj
155 0 obj
<>
endobj
177 0 obj
<>
endobj
103 0 obj
<>
endobj
130 0 obj
<>stream
HUiPSY~i imFآբ ",4DIXa $ ,6"226ۈKcO5PvyKL35gT}u{:ߩ1g'qa!EblI<)C&a/qbfD|"i8vfٳ:$Y]L{#qk?v20p 00h$K!S~_:x7-懤J]
\(2S$,4I.L!2T(JsٷE2~_.MJ}pQDC2SJ|O,"?Ծ=|w6 s熭
>Sa#F`$cp<g:D0'zoŬA߹)J:UiӦL6}l}jt9'ssf;n&cݟxy
pƿyMFC;vR?,nQҫ
Ԋd$
TZP82.0({;d8I$`Xs:;D#>6!|q}v_:.#aC4+mw8'3a|yZ=ćg[b